Quick Answer: Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon agonist from Eli Lilly. It is not FDA-approved and not commercially available outside clinical trials. In the Phase 2 trial published in NEJM (2023), the 12 mg weekly group lost an average of 24.2% of body weight at 48 weeks. Eli Lilly has since reported Phase 3 (TRIUMPH) results; long-term safety is still being established. There is no approved dosing schedule — trial protocols are summarised below with sources.

Retatrutide For Weight Loss

The GLP-1 medications have transformed the weight loss industry  but researchers are developing new therapies that produce even greater results. One of the most discussed next generation obesity treatments is Retatrutide, a triple agonist peptide currently being studied for its effects on weight reduction, appetite suppression and metabolic health.

Use of retatrutide peptide increased after clinical trial data showed extraordinary body weight reductions among participants. Many scientists now believe that it could represent the next major advancement in obesity medicine because it targets multiple hormone pathways at the same time instead of a single mechanism.

What Is Retatrutide?

Retatrutide is an investigational peptide medication which is being developed for obesity and metabolic disease management. It works as a triple hormone receptor agonist which target the following receptors:

1. GLP-1 receptors
2. GIP receptors
3. Glucagon receptors

This triple fuction makes retatrutide prominent from other  medications such as semaglutide or tirzepatide. By activating multiple pathways involved in appetite regulation, insulin sensitivity and energy expenditure, It produces stronger metabolic effects than earlier generations of weight loss medications.

Retatrutide Benefits

Significant Weight Loss Potential

Retatrutide is used for weight loss. Clinical studies involving Retatrutide have shown amazing weight loss outcomes in obesity research.

In a Phase 2 trial that was published in the The New England Journal of Medicine participants achieved up to 24.2% average body weight loss at48 weeks while some higher dose groups gained17.5% weight loss within just24 weeks.

In Phase 3 (TRIUMPH programme) results reported by Eli Lilly, participants on higher doses lost an average of up to 28.3% of body weight over 80 weeks (company-reported results; peer-reviewed publication was pending at the time of writing).

Appetite Suppression

It reduces hunger and food cravings by affecting the satiety hormones and digestive signaling pathways. Many GLP-1 based medications help individuals to feel fuller for a long time but its triple agonist mechanism may amplify these appetite regulating effects.

Improved Metabolic Health

Researchers are also studying retatrutide for:

• insulin sensitivity
• blood sugar regulation
• waist circumference
• metabolic syndrome markers

Because obesity is closely linked to cardiovascular and metabolic disease risk, these broader improvements may become an important part of its long term clinical role.

Retatrutide Dosing Shedule

Retatrutide dosing protocols are still under clinical investigation. However, most research studies use gradual dose escalation schedules to reduce the gastrointestinal side effects.

Retatrutide Dosage Chart

Trial protocols only — retatrutide has no approved dosing schedule. The Phase 2 trial studied weekly doses from 1 mg to 12 mg.

Retatrutide Dosage Calculator

Because peptides are often available in lyophilized powder. Many users search for retatrutide dosage calculators to help determine correct dosing after reconstitution.

Dosage calculations depend on:

1. peptide concentration
2. amount of bacteriostatic water added
3. syringe units
4. desired dose

This is why peptide calculators have become popular among peptide users and researchers.

Use the Retatrutide Dosage Calculator to convert trial doses into mL and syringe units.

How Much Bac Water for 10mg Retatrutide?

The amount of bacteriostatic water added depends on the desired concentration you need and dosing preference. Different users prefer different mixing ratios based on syringe readability and dosing accuracy.

Many individuals use peptide calculators to simplify:

1. mg-to-unit conversions
2. reconstitution math
3. dosing consistency

Accurate calculations are important because peptide concentrations vary significantly between preparations.

Weight Loss on 5mg Retatrutide

Many people researching retatrutide are especially interested in expected weight loss at moderate doses such as 5mg. Clinical trials suggest retatrutide may produce progressive appetite suppression and meaningful body weight reduction over time at 5mg dose.

However results vary based on:

1. diet quality
2. activity levels
3. insulin resistance
4. dosage escalation
5. treatment duration

Retatrutide vs Ozempic

Ozempic works as a GLP-1 receptor agonist while retatrutide targets GLP-1, GIP and glucagon receptors simultaneously. This triple-action mechanism produces stronger weight loss effects.
However, Ozempic has more established long term clinical data because it is already widely approved and prescribed in the United States.

Tirzepatide Versus Retatrutide

Tirzepatide and retatrutide are compared because both are considered next generation obesity treatments. Tirzepatide works as a dual agonist targeting GLP-1 and GIP receptors while retatrutide works on glucagon receptors as a third mechanism.

Retatrutide vs semaglutide 

Both Semaglutide and Retatrutide are injectable weight loss and diabetes drugs but they work differently and early data shows retatrutide produces greater weight loss. 

Retatrutide Side Effects

Like many GLP-1 based medications, retatrutide may cause gastrointestinal side effects during dose escalation.

Symptoms include:

1. nausea
2. diarrhea
3. bloating
4. constipation
5. fatigue
6. appetite suppression

Most side effects appear dose dependent and improve with time as the body adapts.

Frequently Asked Questions

Final Thoughts

Retatrutide represents one of the most amazing next generation obesity therapies currently being studied. Its triple agonist mechanism targeting GLP-1, GIP  and glucagon receptors offer broader metabolic effects than earlier weight loss medications.
It is a major focus in obesity medicine, peptide therapy discussions and metabolic disease research.

Related guides

• Tirzepatide for Weight Loss
• Semaglutide Dosage Chart & Units
• Peptide Dosage Calculator

References

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. https://doi.org/10.1056/NEJMoa2301972
• Eli Lilly TRIUMPH Phase 3 programme — company press releases and ClinicalTrials.gov records.